TY - JOUR
T1 - Impact of Formulation on the Pharmacokinetics of Dutasteride
T2 - Results from Two Phase I Studies
AU - Fossler, Michael
AU - Zhu, John
AU - Roehrborn, Claus
AU - McAleese, Paul
AU - Manyak, Michael
N1 - Publisher Copyright:
© 2016, Springer International Publishing Switzerland.
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Background and Objectives: Dutasteride is currently marketed by GlaxoSmithKline (GSK), either as monotherapy or as a fixed-dose combination with tamsulosin. As part of the project to develop the fixed-dose combination product, alternative formulations of dutasteride were prepared by GSK, and their pharmacokinetic properties were investigated. Methods: Two single-centre, open-label, active-comparator, randomised, three-period crossover studies were performed. The first study evaluated the relative bioavailability of dutasteride 0.5 mg soft gelatin capsule (marketed formulation, reference) versus a dutasteride 0.5 mg hard gelatin capsule and a dutasteride 0.5 mg tablet. The second assessed the relative bioavailability of dutasteride 0.5 mg from soft gelatin capsules containing 300 or 100 mg of mono- and diglycerides of caprylic acid/capric acid (MDC8, an emulsifying agent) versus the marketed formulation. Results: In the first study (n = 36), compared with the marketed soft gelatin capsule formulation, the bioavailability (least squares [LS] means ratio) of the tablet formulation was 76 % (90 % CI 0.68–0.84), and that of the hard gelatin capsule was 73 % (90 % CI 0.66–0.82). Peak exposures were also lower for the tablet (73 %; 90 % CI 0.66–0.81) and hard capsule (71 %; 90 % CI 0.64–0.79) relative to the marketed soft gelatin capsule. In the second study (n = 37), compared with the marketed soft gelatin formulation, the bioavailability (LS means ratio) of the 300 mg MDC8 capsule formulation was 95 % (90 % CI 0.88–1.03), and that of the 100 mg MDC8 capsule formulation was 93 % (90 % CI 0.86–1.00). Peak exposures were also lower for the 300 mg MDC8 (90 %; 90 % CI 0.81–0.99) and 100 mg MDC8 (87 %; 90 % CI 0.79–0.96) formulations. Conclusions: The bioavailability of, and peak exposure to, dutasteride are influenced by the formulation of the administered medication. These studies demonstrate the importance of formulation for obtaining the optimal pharmacokinetic properties of dutasteride.
AB - Background and Objectives: Dutasteride is currently marketed by GlaxoSmithKline (GSK), either as monotherapy or as a fixed-dose combination with tamsulosin. As part of the project to develop the fixed-dose combination product, alternative formulations of dutasteride were prepared by GSK, and their pharmacokinetic properties were investigated. Methods: Two single-centre, open-label, active-comparator, randomised, three-period crossover studies were performed. The first study evaluated the relative bioavailability of dutasteride 0.5 mg soft gelatin capsule (marketed formulation, reference) versus a dutasteride 0.5 mg hard gelatin capsule and a dutasteride 0.5 mg tablet. The second assessed the relative bioavailability of dutasteride 0.5 mg from soft gelatin capsules containing 300 or 100 mg of mono- and diglycerides of caprylic acid/capric acid (MDC8, an emulsifying agent) versus the marketed formulation. Results: In the first study (n = 36), compared with the marketed soft gelatin capsule formulation, the bioavailability (least squares [LS] means ratio) of the tablet formulation was 76 % (90 % CI 0.68–0.84), and that of the hard gelatin capsule was 73 % (90 % CI 0.66–0.82). Peak exposures were also lower for the tablet (73 %; 90 % CI 0.66–0.81) and hard capsule (71 %; 90 % CI 0.64–0.79) relative to the marketed soft gelatin capsule. In the second study (n = 37), compared with the marketed soft gelatin formulation, the bioavailability (LS means ratio) of the 300 mg MDC8 capsule formulation was 95 % (90 % CI 0.88–1.03), and that of the 100 mg MDC8 capsule formulation was 93 % (90 % CI 0.86–1.00). Peak exposures were also lower for the 300 mg MDC8 (90 %; 90 % CI 0.81–0.99) and 100 mg MDC8 (87 %; 90 % CI 0.79–0.96) formulations. Conclusions: The bioavailability of, and peak exposure to, dutasteride are influenced by the formulation of the administered medication. These studies demonstrate the importance of formulation for obtaining the optimal pharmacokinetic properties of dutasteride.
UR - http://www.scopus.com/inward/record.url?scp=84976423769&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84976423769&partnerID=8YFLogxK
U2 - 10.1007/s40261-016-0419-6
DO - 10.1007/s40261-016-0419-6
M3 - Article
C2 - 27356530
AN - SCOPUS:84976423769
SN - 1173-2563
VL - 36
SP - 763
EP - 767
JO - Clinical Drug Investigation
JF - Clinical Drug Investigation
IS - 9
ER -